Clinical

Dataset Information

A Bioequivalence Study of Capecitabine Tablets


ABSTRACT: 1. purpose: To conduct the relative bioavalability study of Capecitabine tablets 500 mg (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus XELODA 500 mg tablets (Manufactured by Roche Pharma AG) 2. Experimental Design: Two-period crossover design 3. Test drug: Capecitabine tablets Reference drug: XELODA 4. Sample size:24

DISEASE(S): Metastatic Breast Cancer Or Metastatic Colorectal Cancer,Colorectal Neoplasms,Breast Neoplasms

PROVIDER: 2144279 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR